Candel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 08/05/22
Candel Therapeutics Announces Release of Initial Data on CAN-2409 in a Phase 2 Clinical Trial Showing Cytotoxic T Cell Response and Disease Control in Patients with Non-Small Cell Lung CancerGlobeNewsWire • 05/26/22
Candel Therapeutics to Present at the H.C. Wainwright Annual Global Investment ConferenceGlobeNewsWire • 05/18/22
Candel Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 05/12/22
Candel Therapeutics to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewsWire • 04/27/22
Candel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 03/29/22
Candel Therapeutics Appoints Seshu Tyagarajan, Ph.D., RAC, as Chief Technical and Development OfficerGlobeNewsWire • 03/02/22
Candel Therapeutics Announces $25 Million Non-dilutive Debt Financing Agreement with Silicon Valley BankGlobeNewsWire • 03/01/22
Candel Therapeutics Appoints Dr. Francesca Barone as Chief Scientific OfficerGlobeNewsWire • 02/03/22
Bionaut Labs and Candel Therapeutics Announce Strategic Collaboration in Precision-Targeted Delivery of Oncolytic Viral ImmunotherapiesGlobeNewsWire • 12/15/21
Candel Therapeutics and Partnership for Accelerating Cancer Therapies (PACT) to Collaborate on Lung Cancer Trial for CAN-2409GlobeNewsWire • 12/10/21
Candel Therapeutics Presents Novel Biomarker Data Demonstrating Immune Activation After Administration of CAN-3110 in Patients with Recurrent High-Grade GliomaGlobeNewsWire • 11/12/21
Candel Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 11/12/21
Candel Therapeutics Announces Upcoming Data Presentations on its Oncolytic Viral ImmunotherapiesGlobeNewsWire • 11/01/21
Candel Therapeutics Announces Patient-Reported Tolerability Data of Intraprostatic Injections in Ongoing Phase 3 Clinical Trial of CAN-2409 in Patients with Localized Prostate CancerGlobeNewsWire • 10/28/21
Candel Therapeutics Appoints Mace L. Rothenberg, MD, as Senior Advisor to the Chief Executive OfficerGlobeNewsWire • 10/19/21
Candel Therapeutics Announces Participation in Upcoming Society for Immunotherapy of Cancer's (SITC) 36th Annual MeetingGlobeNewsWire • 10/04/21
Candel Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 09/08/21
Monday Afternoon Analyst Upgrades and Downgrades: Chesapeake Energy, Traeger and More24/7 Wall Street • 08/23/21
Candel Therapeutics Announces Closing of Initial Public Offering, Including the Partial Exercise of Underwriters' OptionGlobeNewsWire • 08/17/21